ストックスクリーナーアプリを入手
39.60
1.25%
0.49
アフターアワーズ：
38.90
-0.70
-1.77%
前日終値:
$39.11
開ける：
$39.43
24時間の取引高:
514.17K
Relative Volume:
0.59
時価総額：
$1.82B
収益：
-
当期純損益:
$-146.66M
株価収益率:
-14.38
EPS:
-2.7541
ネットキャッシュフロー:
$-133.21M
1週間 パフォーマンス:
+6.62%
1か月 パフォーマンス:
-5.62%
6か月 パフォーマンス:
+1.75%
1年 パフォーマンス:
-21.11%
1日の値動き範囲:
$38.83
$39.91
1週間の範囲:
$37.40
$40.40
52週間の値動き範囲:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
APGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
39.60 | 2.17B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-07 | 繰り返されました | BTIG Research | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-11-25 | 開始されました | Canaccord Genuity | Buy |
| 2024-05-10 | 開始されました | BofA Securities | Buy |
| 2023-12-20 | 開始されました | BTIG Research | Buy |
| 2023-08-08 | 開始されました | Guggenheim | Buy |
| 2023-08-08 | 開始されました | Jefferies | Buy |
| 2023-08-08 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
| 2023-08-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Apogee Therapeutics Inc (APGE) 最新ニュース
Is Apogee Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
What drives Apogee Therapeutics Inc. stock priceExtraordinary earning power - jammulinksnews.com
Apogee Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
What analysts say about Apogee Therapeutics Inc. stockTremendous growth potential - jammulinksnews.com
InvestingPro Fair Value model captures 43% downside in Apogee Therapeutics By Investing.com - Investing.com Canada
Teacher Retirement System of Texas Sells 629 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) - Defense World
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating - MSN
Will Apogee Therapeutics Inc. stock benefit from interest rate changesTop Gaining Low Risk Assets - Newser
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - MSN
What makes Apogee Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
Why Apogee Therapeutics Inc. stock attracts strong analyst attentionLow Risk Stock Strategies - Newser
How Apogee Therapeutics Inc. stock performs during market volatilityStable Growth Stock Picks - Newser
Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Insider Monkey
Analysts Set Apogee Therapeutics Inc. (NASDAQ:APGE) Price Target at $99.00 - Defense World
Rx Rundown: Merck, Gilead Sciences, Apogee Therapeutics and more - Medical Marketing and Media
Stifel reiterates Buy rating on Apogee Therapeutics stock amid positive AD data - Investing.com Nigeria
Trend Tracker for (APGE) - news.stocktradersdaily.com
Apogee falls after results from atopic dermatitis trial - MSN
Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data - Investing.com Canada
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis (APGE) - Seeking Alpha
Gold Falls 1%; ProKidney Shares Spike HigherApogee Therapeutics (NASDAQ:APGE), Blue Gold (NASDAQ:BGL) - Benzinga
Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data By Investing.com - Investing.com South Africa
Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data - Investing.com Nigeria
Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data By Investing.com - Investing.com South Africa
Apogee Therapeutics shares fall 1.66% in premarket after profit-taking and technical selling. - AInvest
Positive Phase II APEX clinical trial of Apogee’s APG777 - The Pharma Letter
Apogee Therapeutics’ (APGE) Outperform Rating Reaffirmed at Wedbush - Defense World
Apogee Therapeutics Target of Unusually Large Options Trading (NASDAQ:APGE) - Defense World
Apogee Therapeutics stock maintains Buy rating at Citi after positive data - Investing.com India
Apogee Therapeutics stock maintains Buy rating at Citi after positive data By Investing.com - Investing.com South Africa
Apogee Therapeutics Inc (APGE) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
大文字化:
|
ボリューム (24 時間):